About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Pfizer, Vertex Execs Are Victims of Facebook Faker; Forbes, WSJ Also Targeted

By Jim Edwards | Apr 29, 2009

Someone is impersonating prominent members of the pharma and biotech world on Facebook, including Vertex Pharmaceuticals chief executive Joshua Boger, a chief science officer at Pfizer and Forbes drug writer Matt Herper. The latter wrote a half-amusing, half-disturbing story for Forbes about how he was duped by the Facebook faker, friending “Rick Weiss,” the former Washington Post science writer, only to later find out that the real Weiss had not sent him a friend request.

Herper even conversed with “Rick Weiss” about a YouTube video they had both seen, and remained convinced he was friends with the real Weiss until he called the Post writer on the phone to check. The faker had somehow friended the real victims, copied their profiles, and then set themselves up with new Facebook accounts under their victim’s identity — thus the fake profiles looked real.

That’s the amusing part. Here’s where it gets disturbing:

This pretender was one of 100 impersonators of scientists, journalists and science policy wonks uncovered by Lucas Laursen, a reporter at Nature, the scientific journal. Most of the people who were copied are somehow linked to the biotech industry, and many are linked to the especially controversial field of embryonic stem cell research. Ruth McKernan, chief scientific officer of Pfizer’s regenerative medicine unit is on the list; so was University of Wisconsin bioethicist Alta Charo, whose thinking about stem cells has been hugely influential.

Herper wasn’t “Rick Weiss’s” only victim; the faker had also friended a Wall Street Journal reporter, a lawyer and a public relations executive.

Facebook has since killed off “Rick Weiss” but the bio-faker’s other identities remain out there. Facebook declined to comment for Herper’s piece.

Image: A digital representation of the real Herper.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • Big Biotech M&A Targets: Who Could Follow Astellas' $3.5B Bid for OSI?

    BNET Pharma - 5 days 16 hours 32 minutes ago

    Last week’s news that Astellas Pharma had launched a $3.5 billion hostile takeover of cancer firm OSI Pharmaceuticals (OSIP) sparked speculation about which other big biotechs could be acquisition targets. Last year was all about mega-mergers: Pfizer/Wyeth, Merck/Schering and Roche/Genentech. The experts don’t expect much of that this...

  • Who's the next biotech buyout target?

    FierceBiotech - 5 days 13 hours 22 minutes ago

    With Astellas Pharma and OSI Pharmaceuticals haggling over price, BNet Pharma wonders which biotechs could be next on the buyout menu. Mega-mergers might have been all the rage in 2009; however, with few targets left, the focus will shift to smaller acquisitions. Big Biotechs Biogen Idec and Gezyme could be on the menu, given Carl Icahn's...

  • Nine medicines now cost more than $200,000 per year.

    PharmaGossip - 20 days 9 hours 43 minutes ago

    Matt Herper has the story

  • AstraZeneca job cuts reflect new landscape

    Financial Times - 5 days 20 hours 43 minutes ago

    When AstraZeneca revealed details last week of 3,500 job cuts across its global research and development operations, it was not just the company’s own employees who felt concerned. The decision by the Anglo-Swedish pharmaceuticals group is the latest in a series of recent restructurings that will have an important impact on the volume of...

  • AstraZeneca?job cuts reflect new landscape

    Financial Times - 6 days 11 hours 11 minutes ago

    When AstraZeneca revealed details last week of 3,500 job cuts across its global research and development operations, it was not just the company’s own employees who felt concerned. The decision by the Anglo-Swedish pharmaceuticals group is the latest in a series of recent restructurings that will have an important impact on the volume of...

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a>)

advertisement
advertisement
advertisement
Click Here